Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call scheduled for March 2, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2022 financial results along with recent corporate developments.

The company's pipeline includes EYP-1901, an investigational treatment in Phase 2 clinical trials utilizing its Durasert® technology for sustained intraocular drug delivery. EyePoint has a track record with four FDA-approved products, including YUTIQ® for posterior segment uveitis, enhancing its position in the ophthalmic therapeutics market.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced on February 16, 2023, the granting of non-statutory stock options to two new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4). A total of 6,000 stock options were issued at an exercise price of $3.70 per share, equal to the closing price on the grant date. The options will vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments. The company is focused on therapeutics for serious eye disorders, leveraging its Durasert® technology.

EyePoint Pharmaceuticals has announced a lease agreement to build a 40,000-square-foot GMP manufacturing facility in Northbridge, Massachusetts, aimed at boosting the production of its retinal disease therapies, particularly EYP-1901 and YUTIQ. The facility is expected to be operational by the second half of 2024, bolstered by $1.9 million in state and local grants, with rent commencing after occupancy. This strategic investment aligns with EyePoint’s commitment to enhancing its manufacturing capabilities and meeting global clinical demands.

CEO Nancy Lurker emphasized that this facility will be vital for clinical development and commercial production, thereby supporting long-term shareholder value.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options to two new employees as part of an inducement award. On January 13, 2023, the company approved stock options for a total of 4,000 shares, each with an exercise price of $5.04, reflecting the stock's closing price on that date. These options vest over four years, with an initial 25% vesting after one year and the remainder in monthly installments. This move aligns with NASDAQ Listing Rule 5635(c)(4) and aims to attract talented personnel to support EyePoint's commitment to developing therapeutics for serious eye disorders.

EyePoint Pharmaceuticals (NASDAQ: EYPT) provided a business update and clinical timelines for 2023, highlighting ongoing Phase 2 trials for its lead product EYP-1901, targeting wet AMD and NPDR. The company estimates 2022 net product revenue exceeding $39.5 million, up from $35.3 million in 2021, with cash reserves around $144 million. Key milestones include topline data from the DAVIO 2 trial expected in 4Q 2023. However, changes in Medicare reimbursement for DEXYCU may significantly impact future revenues.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the promotion of Dr. Jay S. Duker to President while retaining his role as Chief Operating Officer. Dr. Duker has been instrumental in leading the company’s clinical pipeline, achieving positive results in the Phase 1 DAVIO trial for wet age-related macular degeneration (AMD) and initiating two Phase 2 trials for the investigational drug EYP-1901. EyePoint focuses on developing treatments for serious eye disorders, leveraging its Durasert® technology for sustained drug delivery.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced on December 15, 2022, the grant of non-statutory stock options to a new employee as an inducement award. The company issued options to purchase up to 3,000 shares at an exercise price of $2.68 per share, based on the stock's closing price on the grant date. The options vest over four years, with a quarter vesting after one year and the rest in monthly installments, contingent on the employee's continued service.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options totaling 10,700 shares to two new employees as a part of their inducement awards. This follows NASDAQ Listing Rule 5635(c)(4) and aims to attract talent to the company. The options were granted at an exercise price of $4.42 per share, corresponding to the closing stock price on November 15, 2022. The options will vest over four years, with the first 25% vesting on the anniversary of the grant date. EyePoint is focused on developing treatments for serious eye disorders using its Durasert® technology.